Neuralstem, Inc. (NYSE AMEX: CUR) announced today that it has raised a total of $5,228,000 since the beginning of the year, comprised of a previously disclosed $1.5 million private placement of 646,551 common shares at $2.32, priced at a 30 percent premium over the market on the closing, and approximately $3.7 million from warrant exercises.
Neuralstem also is pleased to announce that it received notice from the NYSE Amex that the Company is now in compliance with its listing requirements.
"These funds will help to support the development of our stem cell technology, including our ongoing clinical trial at Emory University," stated Richard Garr, President and CEO of Neuralstem. "We are also pleased that the NYSE Amex has recognized the improvement in Neuralstem's financial position."
SOURCE Neuralstem, Inc.